DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4m5tjt/medipoint) has announced the addition of the "MediPoint: Cardiac Assist Devices - Global Analysis and Market Forecasts" report to their offering.
A global increase in Congestive Heart Failure (CHF) prevalence, combined with improved device adoption rates, will see the worldwide Cardiac Assist Devices (CAD) market to grow by 93% by 2019, says the latest report produced by research and consulting firm The authors.
According to the company's new report*, CAD sales are expected to reach a value of US$2.3 billion in 2019, climbing at a Compound Annual Growth Rate (CAGR) of 18.8% from US$1.1 billion in 2012.
The CAD market, comprising Intra-Aortic Balloon Pumps (IABP), Ventricular Assist Devices (VAD) and Total Artificial Hearts (TAH), is expected to experience increasing revenue due to a lack of available of heart transplants combined with an expanding population suffering from end-stage heart failure. The authors estimates the global CHF population to reach approximately 31 million in 2019, from 2012's total of 25 million.
Rob Littlefield, The authors's Analyst covering Cardiovascular Medical Devices, states: While the prevalence of end-stage congestive heart failure continues to grow, transplantation procedure volumes have remained the same for more than a decade, providing the majority of patients with few options for treatment.
Furthermore, as a result of significant advances in mechanical pump safety and efficacy, many patients are now looking to CAD implantation in lieu of waiting on the donor list for a heart transplantation, which could take years.
VAD is expected to remain the most profitable sector of the CAD market in coming years, driven largely by the adoption of intracorporeal VAD, including Heartware's HVAD and Thoratec's HeartMate II. VAD sector revenue growth is expected to be further supported by increased implementation of CAD in healthier patients, whose condition has not progressed to a point of necessitating heart transplantation.
Additionally, with the advent of percutaneous technologies enabling minimally invasive cardiac support, CAD are being increasingly implemented in patients where surgery is not preferable or not an option. Taking these factors into consideration, The authors forecasts the VAD portion of the global CAD market to reach revenue of US$1.9 billion by 2019 from US$635m in 2012.
The report offers comprehensive analysis of the global Cardiac Assist Device (CAD) Market, including development and sales in the Intra-Aortic Balloon Pump (IABP), Ventricular Assist Device (VAD), and Total Artificial Heart (TAH) global markets.
HeartWare International, Inc.
Medos Medizintechnik AG
MicroMed Cardiovascular, Inc.
SynCardia Systems, Inc.
For more information visit http://www.researchandmarkets.com/research/4m5tjt/medipoint.
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.